BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34824739)

  • 21. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Malekmohammad K; Rafieian-Kopaei M
    Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
    Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK
    Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein.
    Moschovou K; Antoniou M; Chontzopoulou E; Papavasileiou KD; Melagraki G; Afantitis A; Mavromoustakos T
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
    Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
    BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
    Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; BrĂ¡s NF; Jha HC
    J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
    Kalamatianos KG
    Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD.
    Bouback TA; Pokhrel S; Albeshri A; Aljohani AM; Samad A; Alam R; Hossen MS; Al-Ghamdi K; Talukder MEK; Ahammad F; Qadri I; Simal-Gandara J
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
    Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
    Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
    Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Some Antiviral Natural Products to Fight Against Novel Coronavirus (SARS-CoV-2) Using an
    Shah A; Patel V; Parmar B
    Comb Chem High Throughput Screen; 2021; 24(8):1271-1280. PubMed ID: 32881661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
    Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
    Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
    J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein.
    Power H; Wu J; Turville S; Aggarwal A; Valtchev P; Schindeler A; Dehghani F
    Bioorg Chem; 2022 Feb; 119():105574. PubMed ID: 34971947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.
    Yu R; Li P
    J Virol Methods; 2022 Mar; 301():114424. PubMed ID: 34896453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
    Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.
    Panda SK; Sen Gupta PS; Biswal S; Ray AK; Rana MK
    J Proteome Res; 2021 Feb; 20(2):1296-1303. PubMed ID: 33472369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.